ESLDEnd Stage Liver Disease
ESLDEuropean Society for Laser Dermatology (Bassum, Germany)
Copyright 1988-2018, All rights reserved.
References in periodicals archive ?
While we were operating HPTC, simultaneously we were working on completion of our hospital so that we could care for these patients with ESLD soon in our own hospital.
Selected endpoints were development of HCC, ESLD, and progression of liver disease, as measured by the aspartate aminotransferase-to-platelet ratio index (APRI) and fibrosis index based on four factors (FIB-4) scores.
Mesenchymal stem cells (MSCs) present a promising therapeutic method to alleviate ESLD. According to a growing body of evidence in recent years, adipose tissue stem cells (ADSCs), a certain type of MSCs, represent the most promising candidate progenitor cells for transplantation, as they show a stronger commitment to hepatic lineage, as well as higher rates of proliferation, compared to bone marrow mesenchymal stem cells (BM-MSCs) [3, 4].
Patients with ESLD and additional cardiovascular diseases, such as severe aortic regurgitation, do often not present with acceptable clinical conditions for OLTx.
The study population consisted of 244 adult patients (age [greater than or equal to] 19 years) with ESLD who underwent LDLT from September 2010 to July 2014 at Seoul St.
Some centers have advocated isolated LT for children who develop ESLD secondary to TPN before full expected intestinal adaptation occurs.
However, some experts have warned against routine HCV screening of persons in the birth cohort, stating that this recommendation is based on unproven assumptions about the benefit of screening in reducing HCV-related mortality, given that only a minority of infected persons develop end-stage liver disease (ESLD) (5).
This study found that HCV-associated ESLD was a greater cause of death in HIV/HCV-coinfected patients treated with HAART than in HCV-monoinfected patients.
Since then, there has been tremendous progress in the complicated process of liver transplantation, which in 1983 was confirmed to be a valid procedure in cases of end stage liver disease (ESLD), in a consensus by the National Institutes of Health.
Hepatitis B virus- (HBV-) related end stage liver diseases (ESLD) account for over 80% of orthotopic liver transplantations (OLTs) in China, and active HBV replicative status prior to OLT is present in over 50% of patients.